WO2005056607A1 - PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN - Google Patents

PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN Download PDF

Info

Publication number
WO2005056607A1
WO2005056607A1 PCT/HR2004/000039 HR2004000039W WO2005056607A1 WO 2005056607 A1 WO2005056607 A1 WO 2005056607A1 HR 2004000039 W HR2004000039 W HR 2004000039W WO 2005056607 A1 WO2005056607 A1 WO 2005056607A1
Authority
WO
WIPO (PCT)
Prior art keywords
valsartan
cyclodextrin
complex
pentanol
compound
Prior art date
Application number
PCT/HR2004/000039
Other languages
French (fr)
Inventor
Ivica Cepanec
Mladen Litvic
Anamarija Bartolincic
Anita Sporec
Vinka Druskovic
Original Assignee
Belupo-Lijekovi I Kozmetika D.D.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belupo-Lijekovi I Kozmetika D.D. filed Critical Belupo-Lijekovi I Kozmetika D.D.
Publication of WO2005056607A1 publication Critical patent/WO2005056607A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Definitions

  • the patent is related to two new chemical entities: inclusion complex 1 of valsartan (2) and ⁇ -cyclodextrin (3),
  • Valsartan (2) is a well known and very active angiotensin II ATi receptor antagonist, widely used in the treatment of hypertension [P. B ⁇ hlmayer, EP 443,983 (1991); see also: L. Criscione et al., Brit. J. Pharmacol, 110 (1993) 761 ; P. Miiller et al, Eur. J. Clin. Pharmacol., Al (1994) 231].
  • ⁇ -Cyclodextrin molecule consists of 7 glucose molecules connected by alpha- 1,4- glycosidic linkages so that the first and the last glucose molecule together close a toroid structure.
  • Glucose hydroxyl (3 per molecule) groups are located on the external surface of the toroid so that the interior is entirely hydrophobic.
  • Dimensions of the toroid interior are determined by geometry of ⁇ -cyclodextrin structure, that is the number of glucose molecules. Binding of the active substance and ⁇ -cyclodextrin is achieved when a lipophilic (or partially lipophilic) molecule of adequate size enters the hydrophobic interior and forms weak hydrophobic interactions.
  • an inclusion complex In comparison to a simple physical mixture of the same molar ratio, an inclusion complex has characteristic properties regarding solubility, stability, melting point, as well as spectral characteristics.
  • a well known anti- inflammatory and analgesic agent piroxicam is several dozen times more soluble in neutral water when in complex with ⁇ -cyclodextrin than alone.
  • the inclusion complex is thus the key ingredient for the production of the so-called rapid pharmaceutical forms, such as sublingual tablets etc. [D. N. Reddy et al, Indian J. Pharm. Set (1991) 152].
  • the complex 1 made of valsartan (2) and ⁇ -cyclodextrin (3) in any stoichiometric ratio has not yet been described.
  • valsartan (2) reacts with ⁇ -cyclodextrin (3) and produces the mentioned inclusion complex 1.
  • the reactants were mixed in water, lower aliphatic alcohols or mixtures of water and lower alcohols or other organic solvents mixable with water, for 10 minutes to 72 hours at temperatures from 0 °C to ca. 60 °C. The most effective parameters were found to be the temperature of 40-50 °C over the period of 1-3 h, Scheme 1.
  • reaction solvents water, lower aliphatic alcohols, mixtures of water and lower aliphatic alcohols or other water-miscible organic solvents such as: methanol, ethanol, 1-propanol, 2- propanol, 1-butanol, 2-butanol, isobutanol, tert-butanol, 1-pentanol, 2-pentanol, 3- pentanol, isopentanol, tert-pentanol, 1-hexanol, cyclohexanol, acetonitrile, propionitrile, acetone, ethylmethylketone, N,N-dimethyl formamide, N,N-dimethylacetamide, N- methylpyrrolidinone, tetrahydrofuran, 1 ,4-dioxane, dimethoxyethane, diethyleneglycol dimethylether, diethyleneglycol diethylether, tri
  • the complexes 1 and la may be produced by mixing equimolar quantities of valsartan (2) and ⁇ -cyclodextrin (3) in the case of complex 1, or in the molar ratio 1 : 2 in the case of complex la, in any of the mentioned inert solvents at temperatures from 0-60 °C, followed by later evaporation of the reaction solvent to dryness under high vacuum at a temperature below 60 °C.
  • the described alternative technique enables quantitative yield of complex 1 and la isolation with a minimal loss of initial compounds.
  • the characteristics of the complex 1 have been established by IR spectrometry, thermo gravimetric analysis (TGA) and X-Ray powder analysis.
  • Thermogravimetric analysis (TGA) of the inclusion complexes 1 (1 : 1) and la (1 : 2) has shown a slightly different curve of mass loss in relation to the temperature, when compared to the curve of ⁇ -cyclodextrin (3) alone, or the appropriate physical mixture.
  • the significant differences between the roentgenogram of the physical mixtures and of the corresponding complex (1, 1 : 1; la, 1 : 2) shown by X-Ray powder diffraction analysis have clearly confirmed the formation of a new phase.
  • the complexes 1 (1 : 1) and la (1 : 2) are odorless, white crystalline substances, stable in air, and characterized by a significantly increased water solubility in comparison to valsartan alone. This property makes them suitable for the production of pharmaceutical forms, such as tablets, which have very different profiles of active substance release from valsartan alone.
  • a solution of valsartan (2, 10.00 g, 0.023 mol) in 300 ml of acetone was added dropwise with vigorous stirring for 30 minutes to a suspension of ⁇ -cyclodextrin (3, 52.12 g, 0.046 mol) in 300 ml of distilled water heated to 50 °C.
  • the reaction mixture was stirred at 50 °C for 2 hours, and then at temperatures from 50 °C to 10 °C for 3 hours. After the additional 3 hours at 10 °C, the resulting crystalline product was filtered under vacuum, washed out with 3x20 ml of water and acetone mixture (1 :1, V/V), and dried under high- vacuum to a constant mass, for circa 24 hours.
  • a solution of valsartan (2, 10.00 g, 0.023 mol) in 200 ml of isopropanol was added dropwise with vigorous stirring over 15 minutes to a suspension of ⁇ -cyclodextrin (3, 52.12 g, 0.046 mol) in 200 ml of distilled water heated to 50 °C.
  • the reaction mixture was stirred at 50 °C for 2 hours, and then at temperatures from 50 °C down to 10 °C for 2 hours.
  • Valsartan (2, 10.00 g, 0.023 mol) was added to the suspension of ⁇ -cyclodextrin (3, 52.12 g, 0.046 mol) in 500 ml of a mixture of distilled water and acetonitrile (1 :1, V/V) heated to 40 °C.
  • the reaction mixture was stirred at 40°C for 20 hours under a nitrogen atmosphere.
  • the resulting crystalline product was filtered under vacuum, washed out with 3x20 ml of a mixture of water and acetonitrile (1 :1, V/V), and dried under high- vacuum to a constant mass for about 24 hours.
  • Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of ⁇ -cyclodextrin (3, 78.18 g, 0.069 mol) in 800 ml of distilled water.
  • the resulting suspension was stirred at room temperature under a nitrogen atmosphere for 72 hours.
  • the resulting crystalline product was then filtered under vacuum, washed out with 3x50 ml of distilled water and dried under high-vacuum to a constant mass, for circa 20 hours.
  • the final product was 33.08 g of pure complex 1 (stoichiometry 1 : 1) in the form of crystalline white powder, m. p.
  • Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of ⁇ -cyclodextrin (3, 26.10 g, 0.023 mol) in 800 ml of 96% ethanol.
  • the resulting suspension was stirred at room temperature under a nitrogen atmosphere for 72 hours and then evaporated to dryness under high-vacuum at 40 °C.
  • the white crystalline powder was dried under high- vacuum to a constant mass, for circa 20 hours.
  • the result was 35.97 g of pure complex 1 (stoichiometry 1 : 1) in the form of white crystalline powder, m. p.
  • Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of ⁇ -cyclodextrin (3, 26.06 g, 0.023 mol) in 200 ml of a mixture of distilled water and diethyleneglycol dimethylether (1:1, V/V). The resulting suspension was stirred at 40 °C in a nitrogen atmosphere for 24 hours. The crystalline product was filtered under vacuum, washed out with 3x20 ml of distilled water, and dried under high-vacuum for 24 hours. The result was 34.29 g of pure complex la (stoichiometry 1 : 2) in the form of white crystalline powder, m. p.
  • the content of valsartan (2) in the complex la, stoichiometry 1 : 2 is: Calculated: 16.10%; Found: 16.92% Analysis for (2C 42 H 7 o0 35 -C 24 H 29 N 5 0 3 ) CiosHi . gN .
  • Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of ⁇ -cyclodextrin (3, 26.06 g, 0.023 mol) in 300 ml of isopropanol.
  • the resulting suspension was stirred at room temperature in nitrogen atmosphere for 72 hours.
  • Isopropanol from the reaction mixture was then evaporated to circa V_ of the initial volume under high-vacuum at 45-50 °C.
  • the suspension was then cooled to room temperature over 2 hours.
  • the crystalline product was then filtered under vacuum, washed out 3x20 ml with isopropanol, and dried under high-vacuum to a constant mass, for circa 8 h.
  • Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of ⁇ -cyclodextrin (3, 26.06 g, 0.023 mol) in 300 ml of acetone.
  • the resulting suspension was stirred at room temperature under a nitrogen atmosphere for 46 hours.
  • Acetone was then evaporated from the reaction mixture at circa 50 °C under reduced pressure to circa '/_ of the initial volume.
  • the produced suspension was then cooled to 10 °C, and stirred for 3 hours.
  • the crystalline product was filtered under vacuum, washed out with 3x20 ml of cold acetone and dried under high- vacuum to a constant mass for circa 5 hours.
  • the results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 7.
  • the reaction mixture was stirred at 50 °C for 20 hours, and then at temperatures from 50 °C to 10 °C for 5 hours. After the additional 10 hours at 10 °C, the crystalline product was filtered under vacuum, washed out with 3x20 ml of water and acetone mixture (1 :1, V/V), and dried under high- vacuum to a constant mass for circa 24 hours.
  • the results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 7.
  • IR spectrum of the complex 1 (1 : 1) (upper spectrum) compared to the IR spectrum of the physical mixture of valsartan (2) and ⁇ -cyclodextrin (3) in the same molar ratio.
  • IR spectrum of the complex 1 (1 : 1) (upper spectrum) compared to the IR spectrum of the physical mixture of valsartan (2) and ⁇ -cyclodextrin (3) m the same molar ratio (lower spectrum).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The new inclusion complexes of valsartan with β-cyclodextrin: complex 1, stoichiometry 1 : 1, and complex la, stoichiometry 1 : 2 are characterised and described, as well as the process for their production, according to the methods of complexation in a suspension or in a paste, using water, mixtures of organic solvents and water, or in polar water-miscible organic solvents.

Description

PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN
Technical field to which the patent relates: Int. class C 07 F
The patent is related to two new chemical entities: inclusion complex 1 of valsartan (2) and β-cyclodextrin (3),
Figure imgf000002_0001
1 : R = OH
and inclusion complex la, stoichiometry: valsartan : β-cyclodextrin = 1 : 2. Valsartan (2) is a well known and very active angiotensin II ATi receptor antagonist, widely used in the treatment of hypertension [P. Bϋhlmayer, EP 443,983 (1991); see also: L. Criscione et al., Brit. J. Pharmacol, 110 (1993) 761 ; P. Miiller et al, Eur. J. Clin. Pharmacol., Al (1994) 231]. Valsartan (2) is poorly soluble in neutral water at pH= 7 but the complex 1 shows a marked increase in water solubility. This has a direct impact on the bioavailability of valsartan, because it is present in the form of such a complex in pharmaceutical forms. Binding of pharmaceutically active substances that are insoluble or poorly soluble in water at pH= 7, such as valsartan (2), into a complex with β-cyclodextrin (3) greatly increases their aqueous solubility. The result is a faster release of such substances from pharmaceutical forms (such as tablets) based on these complexes.
Figure imgf000003_0001
3: R = OH
The onset of pharmacological activity of the active substance is thus greatly accelerated. β-Cyclodextrin molecule consists of 7 glucose molecules connected by alpha- 1,4- glycosidic linkages so that the first and the last glucose molecule together close a toroid structure. Glucose hydroxyl (3 per molecule) groups are located on the external surface of the toroid so that the interior is entirely hydrophobic. Dimensions of the toroid interior are determined by geometry of β-cyclodextrin structure, that is the number of glucose molecules. Binding of the active substance and β-cyclodextrin is achieved when a lipophilic (or partially lipophilic) molecule of adequate size enters the hydrophobic interior and forms weak hydrophobic interactions. In comparison to a simple physical mixture of the same molar ratio, an inclusion complex has characteristic properties regarding solubility, stability, melting point, as well as spectral characteristics. A large number of inclusion complexes of various cyclodextrins, α-, β-, γ-, with pharmaceutically active substances, whereby valuable properties such as solubility in neutral water are increased, have been described in the literature [T. Loftsson et al., J. Pharm. Set, 85 (1996) 1017; W. Saenger, Angew. Chem., Int. Ed. Engl, 19 (1980) 344; A. R. Hedges, Chem. Rev., 98 (1998) 2035]. For instance, a well known anti- inflammatory and analgesic agent piroxicam is several dozen times more soluble in neutral water when in complex with β-cyclodextrin than alone. The inclusion complex is thus the key ingredient for the production of the so-called rapid pharmaceutical forms, such as sublingual tablets etc. [D. N. Reddy et al, Indian J. Pharm. Set (1991) 152]. To our knowledge, the complex 1 made of valsartan (2) and β-cyclodextrin (3) in any stoichiometric ratio has not yet been described.
This patent relates to the inclusion complexes of valsartan and β-cyclodextrin: complex 1 (stoichiometry: valsartan : β-cyclodextrin = 1 : 1), analogous complex la (stoichiometry: valsartan : β-cyclodextrin = 1 : 2), and the procedure for preparation of these complexes. We found that valsartan (2) reacts with β-cyclodextrin (3) and produces the mentioned inclusion complex 1. The reactants were mixed in water, lower aliphatic alcohols or mixtures of water and lower alcohols or other organic solvents mixable with water, for 10 minutes to 72 hours at temperatures from 0 °C to ca. 60 °C. The most effective parameters were found to be the temperature of 40-50 °C over the period of 1-3 h, Scheme 1.
Figure imgf000005_0001
This is because a rapid formation of the complex 1 takes place at temperatures around 50 °C, while at temperatures over 60-70 °C dissociation of the already formed complex to the initial components occurs. At room temperature, the reaction is slower but also results in the quantitative conversion within circa 20 h.
However, production of the complex 1 from valsartan (2) and β-cyclodextrin (3) in mixtures of water and lower alcohols such as isopropanol takes place at lower temperatures as well, around 0 °C over 48-72 hours, and also with the quantitative conversion of reactants. The following compounds have shown to be suitable reaction solvents: water, lower aliphatic alcohols, mixtures of water and lower aliphatic alcohols or other water-miscible organic solvents such as: methanol, ethanol, 1-propanol, 2- propanol, 1-butanol, 2-butanol, isobutanol, tert-butanol, 1-pentanol, 2-pentanol, 3- pentanol, isopentanol, tert-pentanol, 1-hexanol, cyclohexanol, acetonitrile, propionitrile, acetone, ethylmethylketone, N,N-dimethyl formamide, N,N-dimethylacetamide, N- methylpyrrolidinone, tetrahydrofuran, 1 ,4-dioxane, dimethoxyethane, diethyleneglycol dimethylether, diethyleneglycol diethylether, triethyleneglycol dimethylether, triethyleneglycol diethylether, diethyleneglycol monomethylether, diethyleneglycol monoethylether, and related organic water-miscible solvents. Studies have shown that the volume of reaction solvent in relation to the total mass of reactants, valsartan (2) and β-cyclodextrin (3), should be anywhere in the range from 50 : 1 to 1 : 5. The most practical ratios are in the range from 5 : 1 to 10 : 1.
Alternatively, the complexes 1 and la may be produced by mixing equimolar quantities of valsartan (2) and β-cyclodextrin (3) in the case of complex 1, or in the molar ratio 1 : 2 in the case of complex la, in any of the mentioned inert solvents at temperatures from 0-60 °C, followed by later evaporation of the reaction solvent to dryness under high vacuum at a temperature below 60 °C. The described alternative technique enables quantitative yield of complex 1 and la isolation with a minimal loss of initial compounds. The characteristics of the complex 1 have been established by IR spectrometry, thermo gravimetric analysis (TGA) and X-Ray powder analysis. The stoichiometry of the complex was determined by quantitative HPLC analysis with valsartan (2) as an external quantitative standard. It was found that depending on the initial molar ratio of reactants the result is either the complex 1 with stoichiometry: valsartan : β-cyclodextrin = 1 : 1; or complex la with stoichiometry: valsartan : β- cyclodextrin = 1 : 2.
If (in the reaction shown in the Scheme 1) the molar ratio of reactants is: valsartan : β-cyclodextrin = 1 : 2-5, the result is complex 1, stoichiometry 1 : 1; the use of equimolar quantities of valsartan and β-cyclodextrin results in complex la of stoichiometry: 1 : 2. For the synthesis according to the described alternative technique, with evaporation of the inert reaction solvent under vacuum at temperatures below 60 °C, the used molar ratio of valsartan and β-cyclodextrin correspond to the stoichiometry of the desired complex: 1 : 1 for the complex 1, or 1 : 2 for the complex la. The IR spectrophotometric results of the complex 1 (stoichiometry 1 : 1), the complex la (stoichiometry 1 : 2), and the appropriate physical mixture in the equal molar ratio have shown that there is a significant difference in the characteristic band shifts of specific groups. Thus, for instance, the band shift characteristic for the carboxyl carbonyl group of valsartan, which in the physical mixture of molar ratio = 1 : 1 appears at 1732 cm"1, is in the complex la at 1734 cm" . Furthermore, the band shift characteristic for the amide carbonyl group in the physical mixture appears at 1646 cm" , while in the complex la it appears at 1642 cm"'. Also, there is a difference in wide band shifts, at 3393 cm"1 (physical mixture) and 3389 cm"1 (complex la) respectively, which is characteristic for hydroxyl groups of β-cyclodextrin and NH stretching of valsartan free-tetrazole ring (2), shows that an inclusion complex have been formed. The results of IR spectrophotometric analysis of the complex 1 (1 : 1) and la (1 : 2) were similar but still significantly different.
Thermogravimetric analysis (TGA) of the inclusion complexes 1 (1 : 1) and la (1 : 2) has shown a slightly different curve of mass loss in relation to the temperature, when compared to the curve of β-cyclodextrin (3) alone, or the appropriate physical mixture. The significant differences between the roentgenogram of the physical mixtures and of the corresponding complex (1, 1 : 1; la, 1 : 2) shown by X-Ray powder diffraction analysis have clearly confirmed the formation of a new phase. The complexes 1 (1 : 1) and la (1 : 2) are odorless, white crystalline substances, stable in air, and characterized by a significantly increased water solubility in comparison to valsartan alone. This property makes them suitable for the production of pharmaceutical forms, such as tablets, which have very different profiles of active substance release from valsartan alone.
Example I
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 1, Complex 1
A solution of valsartan (2, 10.00 g, 0.023 mol) in 150 ml of 96% ethanol was added dropwise with vigorous stirring to the suspension of β-cyclodextrin (3, 52.12 g, 0.046 mol) in 150 ml of distilled water heated at 50 °C. The reaction mixture was stirred at 50 °C for 30 minutes, and then at temperatures from 50 °C to 10 °C for another 2 hours. After the additional 2 hours at 10 °C, the resulting crystalline product was filtered under vacuum, washed out with 3x20 ml of water/ethanol mixture (1 :1, V/V), and dried under high-vacuum to a constant mass for circa 24 hours. The result was 28.23 g of pure complex 1 (stoichiometry 1 : 1) in the form of white crystalline powder, m. p. 284.0- 292.6 °C, a single spot on TLC, Rf= 0.42 with dichloromethane/isopropanol/acetic acid (9.5:0.5:0.2) as an eluent.
IR (KBr) v: 3383, 2964, 2927, 2876, 1732 (C=0, carboxyl group), 1620 (C=0, amide group), 1567, 1467, 1453, 1413, 1390, 1369, 1352, 1337, 1296, 1252, 1204, 1158, 1102, 1082, 1028, 1000, 946, 938, 854, 805, 777, 760, 707, 668, 652, 609 cm"1. Stoichiometry of the complex was determined by quantitative HPLC analysis with pharmaceutically pure valsartan (2) as an external quantitative standard on Phenomenex Polar RP column, acetonitrile / 20 mM KH2P04 buffer, pH= 2.5 (50:50, V/V); flow 1.0 ml/min; UV detector at 227 nm, r. t. (valsartan)= 5.01 min. The content of valsartan (2) in the complex 1, stoichiometry 1 :1 is: Calculated: 27.73%; Found: 26.91% Analysis for (C42H7o035-C24H29N503) C66H99N5θ38: Calculated: w(C)= 50.48%, w(H)= 6.35%, w(N)= 4.46%; Found: w(C)= 50.2%, w(H)= 7.1%, w(N)= 4.1%. The results of X-Ray powder analysis and TGA analysis of the product 1 are presented in the Appendix. Example 2
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 1, Complex 1
A solution of valsartan (2, 10.00 g, 0.023 mol) in 300 ml of acetone was added dropwise with vigorous stirring for 30 minutes to a suspension of β-cyclodextrin (3, 52.12 g, 0.046 mol) in 300 ml of distilled water heated to 50 °C. The reaction mixture was stirred at 50 °C for 2 hours, and then at temperatures from 50 °C to 10 °C for 3 hours. After the additional 3 hours at 10 °C, the resulting crystalline product was filtered under vacuum, washed out with 3x20 ml of water and acetone mixture (1 :1, V/V), and dried under high- vacuum to a constant mass, for circa 24 hours. The result was 23.98 g of pure complex 1 (stoichiometry 1 : 1) in the form of white crystalline powder, m. p. 286.3-297.3 °C, a single spot on TLC, Rf= 0.42 with dichloromethane/isopiOpanol/ acetic acid (9.5:0.5:0.2) as an eluent. The IR spectrum, X-Ray powder diffraction, and the HPLC analysis results correspond with the results of the Example 1 product.
Example 3
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 1, Complex 1
A solution of valsartan (2, 10.00 g, 0.023 mol) in 200 ml of isopropanol was added dropwise with vigorous stirring over 15 minutes to a suspension of β-cyclodextrin (3, 52.12 g, 0.046 mol) in 200 ml of distilled water heated to 50 °C. The reaction mixture was stirred at 50 °C for 2 hours, and then at temperatures from 50 °C down to 10 °C for 2 hours. After the additional 24 hours at 10 °C, the resulting crystalline product was filtered under vacuum, washed out with 3x20 ml of a mixture of isopropanol and water (1 :1, V/V), and dried under high-vacuum to a constant mass for 24 hours. The result was 29.97 g of pure complex 1 (stoichiometry 1 : 1) in the form of white crystalline powder, m. p. 284.8-291.9 °C, a single spot on TLC, Rf= 0.42 with dichloromethane/isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 1.
Example 4
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 1, Complex 1
Valsartan (2, 10.00 g, 0.023 mol) was added to the suspension of β-cyclodextrin (3, 52.12 g, 0.046 mol) in 500 ml of a mixture of distilled water and acetonitrile (1 :1, V/V) heated to 40 °C. The reaction mixture was stirred at 40°C for 20 hours under a nitrogen atmosphere. The resulting crystalline product was filtered under vacuum, washed out with 3x20 ml of a mixture of water and acetonitrile (1 :1, V/V), and dried under high- vacuum to a constant mass for about 24 hours. The result was 31.07 g of pure complex 1 (stoichiometry 1 : 1) in the form of white crystalline powder, m. p. 285.4-295.3 °C, a single spot on TLC, Rf= 0.42 with dichloromethane/ isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The IR spectrum, X-Ray powder analysis, and HPLC analysis of the product correspond with results of the Example 1 product.
Example 5
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 1, Complex 1
Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of β-cyclodextrin (3, 78.18 g, 0.069 mol) in 800 ml of distilled water. The resulting suspension was stirred at room temperature under a nitrogen atmosphere for 72 hours. The resulting crystalline product was then filtered under vacuum, washed out with 3x50 ml of distilled water and dried under high-vacuum to a constant mass, for circa 20 hours. The final product was 33.08 g of pure complex 1 (stoichiometry 1 : 1) in the form of crystalline white powder, m. p. 286.4-296.1 °C, a single spot on TLC, Rt= 0.42, with dichloromethane/ isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 1.
Example 6
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 1, Complex 1
Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of β-cyclodextrin (3, 26.10 g, 0.023 mol) in 800 ml of 96% ethanol. The resulting suspension was stirred at room temperature under a nitrogen atmosphere for 72 hours and then evaporated to dryness under high-vacuum at 40 °C. The white crystalline powder was dried under high- vacuum to a constant mass, for circa 20 hours. The result was 35.97 g of pure complex 1 (stoichiometry 1 : 1) in the form of white crystalline powder, m. p. 289.0-297.5 °C, a single spot on TLC, Rf= 0.42 with dichloromethane/isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 1.
Example 7
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 2, Complex la
Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of β-cyclodextrin (3, 26.06 g, 0.023 mol) in 200 ml of a mixture of distilled water and diethyleneglycol dimethylether (1:1, V/V). The resulting suspension was stirred at 40 °C in a nitrogen atmosphere for 24 hours. The crystalline product was filtered under vacuum, washed out with 3x20 ml of distilled water, and dried under high-vacuum for 24 hours. The result was 34.29 g of pure complex la (stoichiometry 1 : 2) in the form of white crystalline powder, m. p. 288.2-291.3 °C, a single spot on TLC, Rf= 0.42 with dichloromethane/isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. IR (KBr) v: 3389, 2960, 2927, 2870, 2739, 1734 (C=0, carboxyl group), 1648, 1624 (C=O, amide group), 1567, 1462, 1454, 1414, 1390, 1369, 1337, 1301, 1252, 1203, 1158, 1102, 1082, 1050, 1028, 999, 946, 938, 855, 777, 760, 707, 669, 652, 610 cm"1. Stoichiometry of the complex was determined by quantitative HPLC analysis with pharmaceutically pure valsartan (2) as an external quantitative standard, on Phenomenex Polar RP column with acetonitrile/20 mM KH2P04 buffer, pH= 2.5 (50:50, V/V); flow 1.0 ml/min; UV detector at 227 nm, r. t. (valsartan)= 5.01 min. The content of valsartan (2) in the complex la, stoichiometry 1 : 2 is: Calculated: 16.10%; Found: 16.92% Analysis for (2C42H7o035-C24H29N503) CiosHi.gN.Oys: Calculated: w(C)= 47.95%, w(H)= 6.30%, w(N)= 2.59%; Found: w(C)= 47.5%, w(H)= 6.1%, w(N)= 2.7%. X-Ray powder analysis and TGA analysis of the product are enclosed in the Appendix.
Example 8
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 2, Complex la
Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of β-cyclodextrin (3, 26.06 g, 0.023 mol) in 300 ml of isopropanol. The resulting suspension was stirred at room temperature in nitrogen atmosphere for 72 hours. Isopropanol from the reaction mixture was then evaporated to circa V_ of the initial volume under high-vacuum at 45-50 °C. The suspension was then cooled to room temperature over 2 hours. The crystalline product was then filtered under vacuum, washed out 3x20 ml with isopropanol, and dried under high-vacuum to a constant mass, for circa 8 h. The result was 31.82 g of pure complex la (stoichiometry 1 : 2) in the form of white crystalline powder, m. p. 288.0-291.4 °C, a single spot on TLC, R 0.42 with dichloromethane/ isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 7.
Example 9
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 2, Complex la
Valsartan (2, 10.00 g, 0.023 mol) was added to a suspension of β-cyclodextrin (3, 26.06 g, 0.023 mol) in 300 ml of acetone. The resulting suspension was stirred at room temperature under a nitrogen atmosphere for 46 hours. Acetone was then evaporated from the reaction mixture at circa 50 °C under reduced pressure to circa '/_ of the initial volume. The produced suspension was then cooled to 10 °C, and stirred for 3 hours. The crystalline product was filtered under vacuum, washed out with 3x20 ml of cold acetone and dried under high- vacuum to a constant mass for circa 5 hours. The product was 34.05 g of pure complex la (stoichiometry 1 : 2) in the form of white powder, m. p. 287.8-291.3 °C, a single spot on TLC, R(= 0.42 with dichloromethane/ isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 7. Example 10
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 2, Complex la
A solution of valsartan (2, 10.00 g, 0.023 mol) in 150 ml of 96% ethanol was added dropwise during 30 minutes to a suspension of β-cyclodextrin (3, 52.12 g, 0.046 mol) in 150 ml of distilled water heated to 50 °C. The reaction mixture was stirred at 50 °C for 20 hours, and then at temperatures from 50 °C to 10 °C for 5 hours. After the additional 10 hours at 10 °C, the crystalline product was filtered under vacuum, washed out with 3x20 ml of water and acetone mixture (1 :1, V/V), and dried under high- vacuum to a constant mass for circa 24 hours. The product was 28.17 g of pure complex la (stoichiometry 1 : 2) in the form of white crystalline powder, m. p. 288.3-291.1 °C, a single spot on TLC, Rf= 0.42 with dichloromethane/isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 7.
Example 11
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 2, Complex la
A solution of valsartan (2, 10.00 g, 0.023 mol) in 200 ml of isopropanol was added dropwise, with vigorous stirring, during 30 minutes to a suspension of β-cyclodextrin (3, 52.12 g, 0.046 mol) in 200 ml of distilled water heated to 50 °C. The reaction mixture was stirred at 40 °C for 48 h, and then at temperatures from 50 °C to 10 °C for 2 hours. After the additional 4 hours at 10 °C, the resulting crystalline product was filtered under vacuum, washed out with 3x20 ml of a water/acetone mixture (1 :1, V/V), and dried under high-vacuum to a constant mass for circa 24 hours. The result was 31.97 g of pure complex la (stoichiometry 1 : 2) in the form of white crystalline powder, m. p. 287.9-291.0 °C, a single spot on TLC, Rt= 0.42 with dichloromethane/ isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotography, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 7.
Example 12
Preparation of the complex of valsartan and β-cyclodextrin, stoichiometry 1 : 2, Complex la
A solution of valsartan (2, 10.00 g, 0.023 mol) in 200 ml of ethanol was added dropwise over 30 minutes to a suspension of β-cyclodextrin (3, 52.21 g, 0.046 mol) in 200 ml of 96% ethanol. The reaction mixture was stirred at 40 °C for 48 hours, and then the resulting suspension was evaporated to dryness under high-vacuum at the maximum temperature of 45 °C. The product was dried under high-vacuum to a constant mass for circa 24 hours. The result was 62.04 g of the pure complex la (stoichiometry 1 : 2) in the form of crystalline powder, m. p. 287.9-291.0 °C, a single spot on TLC, R = 0.42 with dichloromethane/ isopropanol/acetic acid (9.5:0.5:0.2) as an eluent. The results of IR spectrophotometry, X-Ray powder analysis, and HPLC analysis of the product correspond to the results of the product described in the Example 7. The presented examples are supported with the results of IR spectrophotometric (IR) and thermo gravimetric (TGA) analyses, as well as X-Ray diffraction on the complex 1 (1 : 1) and la (1 : 2) powder.
Appendix 1. IR spectrum of the complex 1 (1 : 1) (upper spectrum) compared to the IR spectrum of the physical mixture of valsartan (2) and β-cyclodextrin (3) in the same molar ratio.
Appendix 2. Thermogravimetric curve of complex 1 (1 : 1).
Appendix 3. X-Ray powder analysis of the complex 1 (1 : 1).
Appendix 4. IR spectrum of complex la (1 : 2) (upper spectrum) compared to IR spectrum of complex 1 (1 : 1) (lower spectrum).
Appendix 5. Thermogravimetric curve of the complex la (1 : 2).
Appendix 6. X-Ray powder analysis of the complex la (1 : 2).
Appendix 1. IR spectrum of the complex 1 (1 : 1) (upper spectrum) compared to the IR spectrum of the physical mixture of valsartan (2) and β-cyclodextrin (3) m the same molar ratio (lower spectrum).
Figure imgf000018_0001
_? Appendix 2. Thermogravimetric curve of the complex 1 (1 : 1).
Figure imgf000019_0001
Appendix 3. X-Ray powder analysis of the complex 1 (1 : 1).
Figure imgf000020_0001
X-Rav powder analysis of the complex 1 (1 : 1), Appendix 3.:
Angle theta Intensity Angle theta Intensity (θ) (θ) 4.585 25 25.524 25 6.260 14 25.805 9 7.309 4 26.809 19 9.080 34 27.051 36 9.958 16 27.283 18 10.843 66 27.801 16 11.814 9 28.392 14 12.699 100 29.101 4 14.927 39 29.544 12 15.526 31 30.407 6 16.221 13 30.943 10 17.233 39 31.364 13 17.731 51 32.090 10 18.718 16 32.736 7 18.955 30 34.014 5 19.218 18 34.372 10 19.836 58 35.014 30 20.837 43 35.564 10 21.283 33 36.153 4 21.633 18 37.005 8 23.181 53 37.373 6 23.882 4 37.930 5 24.525 20 39.134 7 25.060 13 Appendix 4. IR spectrum of the complex la (1 : 2) (upper spectrum) compared to the IR spectrum of the complex 1 (1 : 1) (lower spectrum).
Figure imgf000022_0001
Appendix 5. Thermogravimetric curve of the complex la (1 : 2).
Figure imgf000023_0001
Appendix 6. X-Ray powder analysis of the complex la (1 : 2).
Figure imgf000024_0001
X-Ray powder analysis of the complex la (1 : 2), Appendix 6.:
Angle theta Intensity Angle theta Intensity (θ) (θ) 4.699 12 22.757 18 6.423 10 23.122 20 9.026 17 24.482 14 9.946 10 25.127 13 10.842 61 25.898 9 11.737 14 26.798 13 12.631 100 27.263 18 14.869 16 28.710 8 15.548 29 29.551 5 16.241 11 30.405 5 17.311 34 31.305 7 17.746 29 32.043 7 18.085 16 34.153 4 18.900 31 34.842 11 19.794 53 36.899 4 20.842 30 37.268 5 21.180 21 38.237 4 21.697 19

Claims

PATENT CLAIMS:
1. A new chemical compound, which is an inclusion complex of valsartan with β-cyclodextrin, compound 1, with the stoichiometry: valsartan : β-cyclodextrin = 1:1.
Figure imgf000026_0001
1 : R = OH
2. A new chemical compound, which is an inclusion complex of valsartan with β-cyclodextrin, compound la, with the stoichiometry: valsartan : β-cyclodextrin = 1 :2.
3. A process for production of inclusion complex of valsartan with β-cyclodextrin, the compound 1, as claimed in Claim 1, in which valsartan (2) and β-cyclodextrin (3), in the molar ratio: 1 : 1 are mixed in an inert reaction solvent at temperatures from 0 °C to 60 °C, for a period from 10 minutes to 72 hours, where the ratio of complex 1 and the solvent is from 5 : 1 to 1 : 50, followed by drying under high-vacuum at temperatures below 60 °C, or in the molar ratio: 1 : 2-5, under the same conditions with additional isolation by filtration.
4. A process for production of inclusion complex of valsartan with β-cyclodextrin, the compound la, as claimed in Claim 2, in which: valsartan (2) and β-cyclodextrin (3) in the molar ratio: 1 : 2, are mixed in inert reaction solvents at temperatures from 0 °C to 60 °C for 10 minutes to 72 hours, with the ratio of the complex la and the solvent ranging from 5 : 1 to 1 : 50 and subsequent drying under high-vacuum at temperatures below 60 °C, or in the molar ratio: 1 : 1-5, in the same conditions and with subsequent isolation by filtration.
5. A process for production of inclusion complex of valsartan and β-cyclodextrin, compound 1 or la, as claimed in Claims 1., 2., 3., and 4., in which water is used as inert solvent.
6. A process for production of the inclusion complex of valsartan with β-cyclodextrin, compound 1 or la, as claimed in Claims 1., 2., 3., and 4., in which the inert reaction solvent is one of organic solvents such as methanol, ethanol, 1-propanol, 2- propanol, 1-butanol, 2-butanol, isobutanol, tert-butanol, 1-pentanol, 2-pentanol, 3- pentanol, isopentanol, tert-pentanol, 1-hexanol, cyclohexanol, acetonitrile, propionitrile, acetone, ethylmethylketone, N,N-dimethylformamide, N,N-dimethyl acetamide, N-methyl pyrrolidinone, tetrahydrofuraή, 1 ,4-dioxane, dimethoxyethane, diethyleneglycol dimethylether, diethyleneglycol diethylether, triethyleneglycol dimethylether, triethyleneglycol diethylether, diethyleneglycol monomethylether, diethyleneglycol monoethylether and related organic solvents miscible with water.
7. A process for production of the inclusion complex of valsartan with β-cyclodextrin, compound 1 or la, as claimed in Claims 1., 2., 3., 4., 5. and 6., in which the inert reaction solvent used is a mixture of water and organic solvents such as lower aliphatic alcohols such as methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2- butanol, isobutanol, tert-butanol, 1-pentanol, 2-pentanol, 3-pentanol, isopentanol, tert-pentanol, 1-hexanol, cyclohexanol, lower aliphatic nitriles: acetonitrile, propionitrile, lower aliphatic ketones: acetone, ethylmethylketone, lower aliphatic amides: N,N-dimethylformamide, N,N-dimethyl acetamide, N-methylpyrrolidinone, ethereal solvents: tetrahydrofuran, 1,4-dioxane, dimethoxyethane, diethyleneglycol dimethylether, diethyleneglycol diethylether, triethyleneglycol dimethylether, triethyleneglycol diethylether, diethyleneglycol monomethylether, diethyleneglycol monoethylether or other related water-miscible organic solvents.
PCT/HR2004/000039 2003-12-12 2004-10-13 PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN WO2005056607A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HRP20031029A 2003-12-12
HR20031029A HRP20031029A2 (en) 2003-12-12 2003-12-12 Process for production of inclusion complexes of valsartan with?-cylodextrin

Publications (1)

Publication Number Publication Date
WO2005056607A1 true WO2005056607A1 (en) 2005-06-23

Family

ID=34674377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HR2004/000039 WO2005056607A1 (en) 2003-12-12 2004-10-13 PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN

Country Status (2)

Country Link
HR (1) HRP20031029A2 (en)
WO (1) WO2005056607A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877042A2 (en) * 2005-04-18 2008-01-16 Rubicon Research Private Limited Bioenhanced compositions
FR2912061A1 (en) * 2007-02-01 2008-08-08 Aliscience Soc Par Actions Sim Cyclodextrin inclusion complexes of amino acids useful in pharmaceutical, veterinary, nutraceutical, food or cosmetic compositions
CN110314240A (en) * 2018-03-29 2019-10-11 海南皇隆制药股份有限公司 A kind of Valsartan cyclodextrin-metal organic framework composition and preparation method thereof
US10973802B2 (en) 2018-12-14 2021-04-13 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080910A1 (en) * 2001-04-10 2002-10-17 Universidade Federal De Minas Gerais-Ufmg Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
HRP20010543A2 (en) * 2001-07-19 2003-04-30 Belupo Lijekovi I Kozmetika D Process for the preparation of pyroxycam and beta-cyclodextrine complex

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080910A1 (en) * 2001-04-10 2002-10-17 Universidade Federal De Minas Gerais-Ufmg Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications
HRP20010543A2 (en) * 2001-07-19 2003-04-30 Belupo Lijekovi I Kozmetika D Process for the preparation of pyroxycam and beta-cyclodextrine complex

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 20 May 2004 (2004-05-20), XP002312250, retrieved from STN Database accession no. 2004:406462 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1877042A2 (en) * 2005-04-18 2008-01-16 Rubicon Research Private Limited Bioenhanced compositions
EP1877042A4 (en) * 2005-04-18 2011-03-02 Rubicon Res Private Ltd Bioenhanced compositions
FR2912061A1 (en) * 2007-02-01 2008-08-08 Aliscience Soc Par Actions Sim Cyclodextrin inclusion complexes of amino acids useful in pharmaceutical, veterinary, nutraceutical, food or cosmetic compositions
WO2008107569A2 (en) * 2007-02-01 2008-09-12 In Cyclo Cysteine inclusion complexes and compositions containing same
WO2008107569A3 (en) * 2007-02-01 2008-11-06 Aliscience Cysteine inclusion complexes and compositions containing same
CN110314240A (en) * 2018-03-29 2019-10-11 海南皇隆制药股份有限公司 A kind of Valsartan cyclodextrin-metal organic framework composition and preparation method thereof
CN110314240B (en) * 2018-03-29 2023-09-12 海南皇隆制药股份有限公司 Valsartan cyclodextrin-metal organic framework composition and preparation method thereof
US10973802B2 (en) 2018-12-14 2021-04-13 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11413275B1 (en) 2018-12-14 2022-08-16 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan
US11446243B1 (en) * 2019-08-05 2022-09-20 ECI Pharmaceuticals, LLC Oral liquid compositions including valsartan

Also Published As

Publication number Publication date
HRP20031029A2 (en) 2005-08-31

Similar Documents

Publication Publication Date Title
EP1873158B1 (en) Crystals of morphinan derivative and process for producing the same
JP6692941B2 (en) Method for manufacturing and purifying sugammadex
AU750738B2 (en) Crystallization of doxorubicin hydrochloride
WO2005056607A1 (en) PROCESS FOR PRODUCTION OF INCLUSION COMPLEXES OF VALSARTAN WITH β-CYCLODEXTRIN
EP0629621B1 (en) Crystal of quinolonecarboxylic acid derivative hydrate
DK144944B (en) METHOD OF PREPARING D, L-5-METHYLTETRAHYDROPHOLIC ACID OR SALTS THEREOF
WO2000078729A1 (en) Crystalline forms of lansoprazole
WO2003018615A1 (en) Novel crystal of cyclic lipopeptide compound
EP3744712A1 (en) Crystalline forms of mesaconine and preparation method therefor
EP1509500B1 (en) Process for the preparation of the amorphous form of atorvastatin calcium salt
CA2835232C (en) A complex of amorphous tomoxiprole and cyclodextrin with fast dissolution rate and process for the preparation thereof
LU501323B1 (en) Cannabinoid complexes with improved properties
FR2897060A1 (en) RIMONABANT MONOHYDRATE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CN115501186B (en) Flavonol glycoside-citric acid solid dispersion and preparation method thereof
EP4190320A1 (en) Crystalline form of phentermine hydrochloride and process for obtaining same
JPH0741495A (en) 14alpha-hydroxy-4-androstene-3,6,17-trione hydrate crystal and its production
CA3118069C (en) Crystal of cyclic-di-amp sodium salt
US20080242872A1 (en) Amorphous carvedilol phosphate and method of manufacturing thereof
WO2020004358A1 (en) HYDRATE CRYSTAL OF 3',3'-cGAMP
WO2007010838A1 (en) Process for producing alkaline earth metal salt of (-)-hydroxycitric acid
JPH0124767B2 (en)
CN114369134A (en) Lupane triterpenoid derivative meglumine salt amorphous substance and preparation method and application thereof
KR100749162B1 (en) Process for preparing aceclofenac aminoacid salt
CN113004118A (en) Method for preparing hexafluorobutadiene by using high-boiling point strong-polarity solvent
WO1994002177A1 (en) Method of preparation of inclusion compounds of nimesulide with cyclodextrins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase